Cargando…
P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430627/ http://dx.doi.org/10.1097/01.HS9.0000970140.10042.07 |
| _version_ | 1785091011481960448 |
|---|---|
| author | Mashadi-Hossein, Afshin Rytlewski, Julie Shamsuzzaman, MD Basudhar, Debashree Takhar, Mandeep Kostic, Ana Campbell, Timothy B. Manier, Salomon Lin, Yi Martin, Nathan |
| author_facet | Mashadi-Hossein, Afshin Rytlewski, Julie Shamsuzzaman, MD Basudhar, Debashree Takhar, Mandeep Kostic, Ana Campbell, Timothy B. Manier, Salomon Lin, Yi Martin, Nathan |
| author_sort | Mashadi-Hossein, Afshin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430627 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104306272023-08-17 P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS Mashadi-Hossein, Afshin Rytlewski, Julie Shamsuzzaman, MD Basudhar, Debashree Takhar, Mandeep Kostic, Ana Campbell, Timothy B. Manier, Salomon Lin, Yi Martin, Nathan Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430627/ http://dx.doi.org/10.1097/01.HS9.0000970140.10042.07 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Mashadi-Hossein, Afshin Rytlewski, Julie Shamsuzzaman, MD Basudhar, Debashree Takhar, Mandeep Kostic, Ana Campbell, Timothy B. Manier, Salomon Lin, Yi Martin, Nathan P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title | P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title_full | P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title_fullStr | P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title_full_unstemmed | P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title_short | P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS |
| title_sort | p809: baseline characteristics identifying patients with multiple myeloma treated with idecabtagene viceleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430627/ http://dx.doi.org/10.1097/01.HS9.0000970140.10042.07 |
| work_keys_str_mv | AT mashadihosseinafshin p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT rytlewskijulie p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT shamsuzzamanmd p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT basudhardebashree p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT takharmandeep p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT kosticana p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT campbelltimothyb p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT maniersalomon p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT linyi p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents AT martinnathan p809baselinecharacteristicsidentifyingpatientswithmultiplemyelomatreatedwithidecabtageneviceleucelidecelbb2121whoareatriskforsevererefractoryinflammatoryadverseevents |